To understand whether GSK3β inhibition plays a major role in mediating TRAIL-TZD-induced apoptosis or increased TRAIL sensitivity in cancer cells, we pretreated cells with different pharmacological inhibitors of GSK3β- CHIR 99021, GSK3β inhibitor VIII and Kenpaullone followed by treatment with TRAIL alone or a combination of TRAIL and TZD. Here, GSK3B is linked to cancer.